Beta blockers in the management of chronic kidney disease

Kidney International
G BakrisE Ritz

Abstract

The sympathetic nervous system modulates renal function through its receptors namely beta1 (cardiac output and renin release), alpha1 (systemic and renovascular constriction), and beta2 renovascular dilation. Sympathetic overactivity is commonly seen in chronic kidney disease (CKD) and is an important contributor to increasing the risk of cardiovascular events as well as increasing renal disease progression. Recent evaluations of drug use in people with CKD shows a remarkably low percentage of patients receiving beta-blockers, especially in more advanced stage CKD when cardiovascular risk is higher. This is in large part due to tolerability of these agents. Moreover, water-soluble beta-blockers such as atenolol and metoprolol are dialyzable and require supplementation to avoid exacerbation of arrhythmias following dialysis. Newer vasodilating beta-blockers have better tolerability and different effects on renal hemodynamics as well as metabolic variables. These effects are related to the relative alpha1-blocking effect of agents such as carvedilol and labetolol, with carvedilol having relatively greater alpha-blocking effects. Few studies evaluate beta-blockers on cardiovascular risk in CKD patients. Studies with carvedilol dem...Continue Reading

References

Jan 1, 1992·The Clinical Investigator·A G Dupont
Jan 1, 1992·Journal of Cardiovascular Pharmacology·K Tomita, F Marumo
Mar 28, 1992·BMJ : British Medical Journal·P T Sawicki, M Berger
Jan 10, 1993·The New England Journal of Medicine·R L ConverseR G Victor
Feb 8, 1992·BMJ : British Medical Journal·S BjörckM Aurell
Jan 1, 1991·Journal of Cardiovascular Pharmacology·S MikiS Yuasa
Jan 1, 1991·Current Medical Research and Opinion·H TindallJ A Davies
Mar 28, 1985·The New England Journal of Medicine·M E WilliamsF H Epstein
Jan 1, 1986·American Journal of Nephrology·P ZechJ F Poncet
Jun 6, 1987·British Medical Journal·H H ParvingP A Svendsen
Jan 1, 1985·European Journal of Clinical Pharmacology·K P OhmanB E Karlberg
Sep 1, 1981·Journal of Cardiovascular Pharmacology·C BarbieriA Bertazzoni
Mar 1, 1984·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G SuginoD T O'Connor
Jul 1, 1980·British Journal of Clinical Pharmacology·R WilkinsonJ D Harry
Jun 1, 1982·British Journal of Clinical Pharmacology·P L MaliniB Magnani
Mar 1, 1980·Clinical Pharmacokinetics·K U SeilerO Wassermann
Jan 1, 1981·European Journal of Clinical Pharmacology·W KirchM Schäfer
Oct 1, 1994·BMJ : British Medical Journal·T HannedoucheJ M Suo
May 1, 1993·Journal of Clinical Pharmacology·K C Abbott, G Bakris
Jun 1, 1996·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·K AmannE Ritz
Apr 1, 1996·European Heart Journal·T YoshikawaM R Bristow
Feb 12, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·G ZuanettiE Ritz
Sep 17, 1998·Archives of Internal Medicine·M Rahman, M C Smith
Nov 20, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G Eknoyan
Apr 29, 1999·The New England Journal of Medicine·G LigtenbergH A Koomans
Sep 29, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·K Amann, E Ritz

Citations

Nov 2, 2011·Internal and Emergency Medicine·Francesco P Schena
Nov 13, 2012·Current Heart Failure Reports·Nael HawwaW H Wilson Tang
Jan 8, 2008·Current Hypertension Reports·Rashida BlakeIvonne Hernandez Schulman
Jan 8, 2008·Current Hypertension Reports·Eberhard Ritz, Lars Christian Rump
Jun 6, 2013·Current Hypertension Reports·Sebastian EwenFelix Mahfoud
Jul 2, 2009·Clinical and Experimental Pharmacology & Physiology·Robert A AugustyniakR G Victor
Feb 7, 2008·Seminars in Dialysis·Seth B Furgeson, Michel Chonchol
Aug 25, 2012·Cardiology Research and Practice·Jeanie Park
Dec 9, 2010·Circulation. Cardiovascular Quality and Outcomes·Ellen FunkhouserCatarina I Kiefe
Jun 24, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Masanori KonishiMitsuaki Isobe
Oct 8, 2013·International Heart Journal·Chang Seong KimKorea Acute Myocardial Infarction Registry Investigators
Jun 12, 2010·Vascular Health and Risk Management·David FeldmanRandy K Wexler
May 19, 2012·Clinical Journal of the American Society of Nephrology : CJASN·Pantelis A SarafidisKatie Vinen
Jan 29, 2013·Current Hypertension Reports·Eva E VinkP J Blankestijn
Dec 8, 2010·Heart Failure Reviews·Savina Nodari, Alberto Palazzuoli
Mar 23, 2012·Postgraduate Medicine·Hassan FaresHector O Ventura
Jan 19, 2016·Journal of the American Society of Hypertension : JASH·James RitchiePhilip A Kalra
Dec 8, 2006·Expert Opinion on Pharmacotherapy·Gregg C Fonarow
Jun 11, 2011·International Journal of Nephrology·Andrew A HouseClaudio Ronco
Sep 18, 2012·The Medical Clinics of North America·Robert T ColeJaved Butler
Sep 25, 2012·Heart Failure Clinics·Ragavendra R Baliga, James B Young
Sep 21, 2007·Kidney International·G M J M WeltenD Poldermans
Jun 19, 2010·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Andrew A HouseClaudio Ronco
Apr 23, 2010·Journal of the American Society of Hypertension : JASH·Carlos Feldstein, Stevo Julius
Jan 1, 2016·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Matthew A RobertsBLOCADE Study Collaborative Group
Sep 2, 2008·Heart Failure Clinics·Abhijit A Shinde, Allen S Anderson
Jan 15, 2008·International Journal of Cardiology·Colin J PetrieRobin A P Weir
Jan 1, 2010·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Rodica Pop-BusuiEva L Feldman
May 10, 2008·Cardiovascular Therapeutics·Firas A Ghanem, Assad Movahed
Jul 9, 2008·The Journal of Clinical Hypertension·C Venkata S Ram
Jul 9, 2008·The Journal of Clinical Hypertension·D A Sica
Nov 11, 2014·Nephrology·Matthew A RobertsBLOCADE Study Collaborative Group
Jul 16, 2015·Clinical and Experimental Pharmacology & Physiology·Yuriko YonekuraShinichi Nishi
Jul 20, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Jamie L FleetAmit X Garg
Jun 15, 2015·Current Hypertension Reports·Ibrahim M Salman
May 13, 2015·International Urology and Nephrology·Beata Franczyk-SkóraJacek Rysz
May 1, 2015·Canadian Journal of Physiology and Pharmacology·Hala Salah Abdel Kawy
Jun 4, 2013·The Journal of Emergency Medicine·Nathan R HootKenneth H Palm
Sep 3, 2011·Journal of the American College of Cardiology·Sunil V BadveVlado Perkovic

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.